Error loading player: No playable sources found

Player size: small large

2145

MASLD For the Non-Hepatologist

Date

May 18, 2024

SOCIETY: AASLD

Presentation:

RISK STRATIFICATION IN REFERRALS FOR MASLD: GI ASSESSMENT

METALD VS ALD

TREATMENT OF MASLD: PHARMACOTHERAPY AND BARIATRIC SURGERY

Moderators

Weill Cornell Medical College

University of Michigan Medical School

Speakers

University of California San Diego

Sujit Janardhan

General

Education and Training

Tracks

Related Products

Thumbnail for Organoids, Tissue-On-A-Chip Human Microtissues: New Tools For The Study Of Liver and Gastrointestinal Diseases

Organoids, Tissue-On-A-Chip Human Microtissues: New Tools For The Study Of Liver and Gastrointestinal Diseases

SOCIETY: AASLD

Thumbnail for TREATMENT OF MASLD: PHARMACOTHERAPY AND BARIATRIC SURGERY

TREATMENT OF MASLD: PHARMACOTHERAPY AND BARIATRIC SURGERY

Thumbnail for NAFLDâ€™s Got a New Name Now - Deeper Dive Into MASLD/SLD

NAFLDâ€™s Got a New Name Now - Deeper Dive Into MASLD/SLD

SOCIETY: AASLD

Thumbnail for AUTOMATED BODY COMPOSITION AND LIVER AND SPLEEN ANALYSIS ARE ASSOCIATED WITH MORTALITY, INCIDENT CIRRHOSIS, AND HEPATIC DECOMPENSATION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

AUTOMATED BODY COMPOSITION AND LIVER AND SPLEEN ANALYSIS ARE ASSOCIATED WITH MORTALITY, INCIDENT CIRRHOSIS, AND HEPATIC DECOMPENSATION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

Background: Body composition measures including sarcopenia, visceral fat volume, and subcutaneous fat volume are associated with fibrosis stage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)…